Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMVYNJZ)

Drug Name
BUTAPROST Drug Info
Synonyms
Butaprost; (R)-Butaprost; 69648-38-0; UNII-HP16WVP23Y; TR-4979; HP16WVP23Y; NCGC00165753-01; Butaprostum; (1R,2R,3R)-3-Hydroxy-2-[(1E,4R)-4-hydroxy-4-(1-propylcyclobutyl)-1-butenyl]-5-oxo-cyclopentaneheptanoic acid methyl ester; Butaprostum [Latin]; Bay q 4218; Butaprost [USAN:INN:BAN]; Butaprost (free acid); AC1NSJVB; Butaprost (USAN/INN); DSSTox_RID_83186; DSSTox_CID_28919; SCHEMBL94764; DSSTox_GSID_48993; CHEMBL271896; GTPL3379; DTXSID8048993; BDBM85602; BAY-Q-4218; ZINC4215145; Tox21_113480; MFCD00867055; 1090AH; PDSP2_001674
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
5311035
CAS Number
CAS 69648-38-0
TTD Drug ID
DMVYNJZ

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Approved Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Prostaglandin E2 receptor EP1 (PTGER1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
AS-013 DMD7XWS Thrombosis DB61-GB90 Phase 3 [8]
PGF2alpha DM4XAU7 Solid tumour/cancer 2A00-2F9Z Clinical trial [9]
ZD6416 DM46JIR Pain MG30-MG3Z Discontinued in Phase 2 [10]
ONO-8130 DMBDCL4 Pollakiuria MF50.1 Terminated [11]
ONO-8711 DM2VRK7 Pain MG30-MG3Z Terminated [12]
U46619 DM13FX4 Discovery agent N.A. Investigative [9]
carbacyclin DMMBQYE Discovery agent N.A. Investigative [13]
PGD2 DMYDW6J Discovery agent N.A. Investigative [14]
M&B 28767 DMJQG82 Discovery agent N.A. Investigative [15]
cicaprost DM7ZJ4H Discovery agent N.A. Investigative [13]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Prostaglandin E2 receptor EP4 (PTGER4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
16,16-dimethyl-PGE2 DMNF38S Stem cell engraftment QB63.8 Phase 2 [15]
RQ-00000007 (oral) DMMYTRU Pain MG30-MG3Z Phase 2 [16]
ONO-AE1-437 DMCUGI8 Asthma CA23 Phase 2 [17]
BGC-20-1531 DMS2MQ5 Migraine 8A80 Phase 2 [18]
IK-007 DMBLFPN Non-small-cell lung cancer 2C25 Phase 1/2 [19]
TPST-1495 DM3GSB2 Solid tumour/cancer 2A00-2F9Z Phase 1 [20]
E7046 DMFVT43 Rectal adenocarcinoma 2B92 Phase 1 [21]
ONO-4232 DMO4SD2 Acute heart failure BD10-BD13 Phase 1 [22]
ONO-4578 DME63VK Solid tumour/cancer 2A00-2F9Z Phase 1 [21]
AN0025 DMGSYPY Aggressive cancer 2A00-2F9Z Phase 1 [23]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Prostaglandin E2 receptor EP2 (PTGER2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dinoprostone DMTYOPD Medical abortion JA00.1Z Approved [2]
Mycophenolate mofetil DMPQAGE Hepatosplenic T-cell lymphoma Approved [24]
Alprostadil DMWH7NQ Aorta coarctation Approved [25]
Iloprost DMVPZBE Pulmonary arterial hypertension BB01.0 Approved [26]
Omidenepag isopropyl DMUX7Z8 Glaucoma/ocular hypertension 9C61 Approved [27]
LAROPIPRANT DM5FABJ Coronary heart disease BA80.Z Phase 4 [28]
16,16-dimethyl-PGE2 DMNF38S Stem cell engraftment QB63.8 Phase 2 [15]
CP-533536 DMZEJLB Osteoporosis FB83.0 Phase 2 [29]
Taprenepag DM1TSHL Glaucoma/ocular hypertension 9C61 Phase 2 [30]
TPST-1495 DM3GSB2 Solid tumour/cancer 2A00-2F9Z Phase 1 [20]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Prostaglandin F2-alpha receptor (PTGFR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dinoprostone DMTYOPD Medical abortion JA00.1Z Approved [2]
Latanoprost DMI5OXG Ocular hypertension 9C61.01 Approved [31]
BOL-303259-X DM2EXC5 Open-angle glaucoma 9C61 Approved [32]
Tafluprost DMFC41K Glaucoma/ocular hypertension 9C61 Approved [33]
Carboprost Tromethamine DMS3508 Abortion JA00 Approved [34]
Travoprost DM20K91 Ocular hypertension 9C61.01 Approved [35]
LAROPIPRANT DM5FABJ Coronary heart disease BA80.Z Phase 4 [28]
PGF2ALPHA-IE DM5DAP3 Glaucoma/ocular hypertension 9C61 Phase 3 [36]
ONO-9054 DM5O6GC Glaucoma/ocular hypertension 9C61 Phase 2 [37]
PDC-41 DM74YO8 Dysmenorrhea GA34.3 Phase 1 [38]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Prostaglandin E2 receptor EP3 (PTGER3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
16,16-dimethyl-PGE2 DMNF38S Stem cell engraftment QB63.8 Phase 2 [15]
ONO-9054 DM5O6GC Glaucoma/ocular hypertension 9C61 Phase 2 [37]
PGF2alpha DM4XAU7 Solid tumour/cancer 2A00-2F9Z Clinical trial [15]
DG041 DMVO9WM Peripheral vascular disease BD4Z Discontinued in Phase 2 [39]
GR-63799X DM13GK8 Asthma CA23 Discontinued in Phase 1 [40]
U46619 DM13FX4 Discovery agent N.A. Investigative [13]
carbacyclin DMMBQYE Discovery agent N.A. Investigative [15]
PGD2 DMYDW6J Discovery agent N.A. Investigative [9]
butaprost (free acid form) DM5MZHP Discovery agent N.A. Investigative [13]
M&B 28767 DMJQG82 Discovery agent N.A. Investigative [15]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By 11-beta-hydroxysteroid dehydrogenase 1 (HSD11B1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Methotrexate DM2TEOL Anterior urethra cancer Approved [41]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [42]
Methylprednisolone DM4BDON Acute adrenal insufficiency Approved [41]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [43]
Isotretinoin DM4QTBN Acne vulgaris ED80 Approved [44]
Testosterone DM7HUNW Hot flushes GA30 Approved [45]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [46]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [47]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [48]
Fenofibrate DMFKXDY Coronary atherosclerosis Approved [42]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Steroid hormone receptor ERR1 (ESRRA)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [49]
Methotrexate DM2TEOL Anterior urethra cancer Approved [50]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [51]
Lindane DMB8CNL Infestations of lice and scabies 1G00.Z Approved [52]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [53]
Bortezomib DMNO38U Leukemia Approved [54]
Dinoprostone DMTYOPD Medical abortion JA00.1Z Approved [7]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [55]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [55]
DTI-015 DMXZRW0 Brain cancer 2A00 Approved [56]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cyclic AMP-dependent transcription factor ATF-3 (ATF3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [57]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [58]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [59]
Methotrexate DM2TEOL Anterior urethra cancer Approved [60]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [61]
Deoxycholic acid DM3GYAL Subcutaneous fat disorder EF02 Approved [62]
Quercetin DM3NC4M Obesity 5B81 Approved [63]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [42]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [64]
Acetic Acid, Glacial DM4SJ5Y infection in the ear canal AA0Y Approved [65]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By NAD-dependent protein deacetylase sirtuin-1 (SIRT1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [66]
Selenium DM25CGV N. A. N. A. Approved [67]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [59]
Quercetin DM3NC4M Obesity 5B81 Approved [68]
Isoniazid DM5JVS3 Latent tuberculosis infection Approved [69]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [70]
Prasterone DM67VKL Chronic obstructive pulmonary disease CA22 Approved [71]
Hydroquinone DM6AVR4 Melasma ED60.1 Approved [72]
Testosterone DM7HUNW Hot flushes GA30 Approved [73]
Olaparib DM8QB1D Ovarian cancer 2C73 Approved [74]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Beta-2 adrenergic receptor (ADRB2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Salmeterol DMIEU69 Allergic asthma CA23.0 Approved [75]
Bambuterol DMKLSHF Asthma CA23 Approved [76]
Terbutaline DMD4381 Asthma CA23 Approved [77]
Salbutamol DMN9CWF Acute asthma CA23 Approved [78]
Imipramine DM2NUH3 Depression 6A70-6A7Z Approved [79]
Methotrexate DM2TEOL Anterior urethra cancer Approved [80]
Epinephrine DM3KJBC Acute asthma CA23 Approved [81]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [82]
Liothyronine DM6IR3P Congenital hypothyroidism Approved [83]
Ergotidine DM78IME Osteoarthritis FA00-FA05 Approved [84]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Interleukin-23 subunit alpha (IL23A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Methotrexate DM2TEOL Anterior urethra cancer Approved [41]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [85]
Methylprednisolone DM4BDON Acute adrenal insufficiency Approved [41]
Misoprostol DMHVJFK Medical abortion JA00.1Z Approved [6]
Zoledronate DMIXC7G Adenocarcinoma 2D40 Approved [54]
Azathioprine DMMZSXQ Lupus nephritis 4A40.0Y Approved [41]
Bortezomib DMNO38U Leukemia Approved [86]
Cupric Sulfate DMP0NFQ Fungal infection 1F29-1F2F Approved [87]
Diclofenac DMPIHLS Chronic renal failure GB61.Z Approved [41]
Prednisolone DMQ8FR2 Acute adrenal insufficiency Approved [41]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Prostaglandin E2 receptor EP1 (PTGER1) TTG1QMU PE2R1_HUMAN Antagonist [2]
Prostaglandin E2 receptor EP2 (PTGER2) TT1ZAVI PE2R2_HUMAN Antagonist [2]
Prostaglandin E2 receptor EP3 (PTGER3) TTPNGDE PE2R3_HUMAN Antagonist [2]
Prostaglandin E2 receptor EP4 (PTGER4) TT79WV3 PE2R4_HUMAN Antagonist [2]
Prostaglandin F2-alpha receptor (PTGFR) TTT2ZAR PF2R_HUMAN Antagonist [2]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
11-beta-hydroxysteroid dehydrogenase 1 (HSD11B1) OTO7FJA9 DHI1_HUMAN Gene/Protein Processing [3]
Beta-2 adrenergic receptor (ADRB2) OTSDOX4Q ADRB2_HUMAN Gene/Protein Processing [4]
Cyclic AMP-dependent transcription factor ATF-3 (ATF3) OTC1UOHP ATF3_HUMAN Gene/Protein Processing [5]
Interleukin-23 subunit alpha (IL23A) OTYO99HC IL23A_HUMAN Gene/Protein Processing [6]
NAD-dependent protein deacetylase sirtuin-1 (SIRT1) OTAYZMOY SIR1_HUMAN Gene/Protein Processing [5]
Steroid hormone receptor ERR1 (ESRRA) OTTDTUSP ERR1_HUMAN Gene/Protein Processing [7]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3379).
2 Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44.
3 PTGER1 and PTGER2 receptors mediate regulation of progesterone synthesis and type 1 11beta-hydroxysteroid dehydrogenase activity by prostaglandin E2 in human granulosa lutein cells. J Endocrinol. 2007 Sep;194(3):595-602.
4 Dual regulation of 2-adrenoceptor messenger RNA expression in human lung fibroblasts by 2-cAMP signaling; delayed upregulated inhibitors oppose a rapid in onset, direct stimulation of gene expression. Naunyn Schmiedebergs Arch Pharmacol. 2014 Jul;387(7):649-57. doi: 10.1007/s00210-014-0971-7. Epub 2014 Apr 8.
5 Prostaglandin E2 down-regulates sirtuin 1 (SIRT1), leading to elevated levels of aromatase, providing insights into the obesity-breast cancer connection. J Biol Chem. 2019 Jan 4;294(1):361-371.
6 Prostaglandin E2 regulates Th17 cell differentiation and function through cyclic AMP and EP2/EP4 receptor signaling. J Exp Med. 2009 Mar 16;206(3):535-48. doi: 10.1084/jem.20082293. Epub 2009 Mar 9.
7 Estrogen receptor-related receptor alpha mediates up-regulation of aromatase expression by prostaglandin E2 in prostate stromal cells. Mol Endocrinol. 2010 Jun;24(6):1175-86.
8 Effect of lipo-pro-prostaglandin E1, AS-013 on rat inner ear microcirculatory thrombosis. Prostaglandins Leukot Essent Fatty Acids. 1998 Sep;59(3):203-7.
9 Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes. Eur J Pharmacol. 1997 Dec 11;340(2-3):227-41.
10 The prostaglandin E2 receptor-1 (EP-1) mediates acid-induced visceral pain hypersensitivity in humans. Gastroenterology. 2003 Jan;124(1):18-25.
11 ONO-8130, a selective prostanoid EP1 receptor antagonist, relieves bladder pain in mice with cyclophosphamide-induced cystitis. Pain. 2011 Jun;152(6):1373-81.
12 Chemopreventive effects of ONO-8711, a selective prostaglandin E receptor EP(1) antagonist, on breast cancer development. Carcinogenesis. 2001 Dec;22(12):2001-4.
13 The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93.
14 Cloned human EP1 prostanoid receptor pharmacology characterized using radioligand binding techniques. J Pharm Pharmacol. 2002 Apr;54(4):539-47.
15 Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24.
16 Clinical pipeline report, company report or official report of Avarx.
17 An EP4 receptor agonist prevents indomethacin-induced closure of rat ductus arteriosus in vivo. Pediatr Res. 2004 Oct;56(4):586-90.
18 BGC20-1531, a novel, potent and selective prostanoid EP4 receptor antagonist: a putative new treatment for migraine headache. Br J Pharmacol. 2009 January; 156(2): 316-327.
19 Grapiprant: an EP4 prostaglandin receptor antagonist and novel therapy for pain and inflammation. Vet Med Sci. 2015 Dec 21;2(1):3-9.
20 Clinical pipeline report, company report or official report of Tempest Therapeutics.
21 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
22 ONO-4232, an EP4-selective Agonist, Improves Left Ventricular Diastolic Dysfunction and Ameliorates Acute and Chronic Heart Failure in Animal Models. Circulation. 2012; 126: A15345.
23 AN0025, a novel antagonist of PGE2-receptor E-type 4 (EP4), in combination with total neoadjuvant treatment of advanced rectal cancer. Radiother Oncol. 2023 Aug;185:109669.
24 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 341).
25 Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24.
26 Exploration of prostanoid receptor subtype regulating estradiol and prostaglandin E2 induction of spinophilin in developing preoptic area neurons. Neuroscience. 2007 May 25;146(3):1117-27.
27 Clinical pipeline report, company report or official report of Santen Pharmaceutical.
28 Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydroc... J Med Chem. 2007 Feb 22;50(4):794-806.
29 Pfizer. Product Development Pipeline. March 31 2009.
30 A phase 2, randomized, dose-response trial of taprenepag isopropyl (PF-04217329) versus latanoprost 0.005% in open-angle glaucoma and ocular hypertension. Curr Eye Res. 2011 Sep;36(9):809-17.
31 PGF(2alpha) FP receptor contributes to brain damage following transient focal brain ischemia. Neurotox Res. 2009 Jan;15(1):62-70.
32 Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating prostaglandin F2alpha agonist, in preclinical models. Exp Eye Res. 2011 Sep;93(3):250-5.
33 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
34 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
35 Prostaglandin subtype-selective and non-selective IOP-lowering comparison in monkeys. J Ocul Pharmacol Ther. 2009 Feb;25(1):1-8.
36 Role of nitric oxide in PGF2 alpha-induced ocular hyperemia. Exp Eye Res. 1994 Oct;59(4):401-7.
37 IOP-Lowering Effect of ONO-9054, A Novel Dual Agonist of Prostanoid EP3 and FP Receptors, in Monkeys. Invest Ophthalmol Vis Sci. 2015 Apr;56(4):2547-52.
38 THG113: a novel selective FP antagonist that delays preterm labor. Semin Perinatol. 2002 Dec;26(6):389-97.
39 BAY x 1005 attenuates atherosclerosis in apoE/LDLR - double knockout mice. J Physiol Pharmacol. 2007 Sep;58(3):583-8.
40 Effects of the prostanoid EP3-receptor agonists M&B 28767 and GR 63799X on infarct size caused by regional myocardial ischaemia in the anaesthetized rat. Br J Pharmacol. 1999 Feb;126(4):849-58.
41 Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration. Arthritis Res Ther. 2009;11(1):R15.
42 Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
43 Adipocyte differentiation, mitochondrial gene expression and fat distribution: differences between zidovudine and tenofovir after 6 months. Antivir Ther. 2009;14(8):1089-100. doi: 10.3851/IMP1457.
44 Retinoic acid and its 4-oxo metabolites are functionally active in human skin cells in vitro. J Invest Dermatol. 2005 Jul;125(1):143-53.
45 Testosterone stimulates adipose tissue 11beta-hydroxysteroid dehydrogenase type 1 expression in a depot-specific manner in children. J Clin Endocrinol Metab. 2010 Jul;95(7):3300-8.
46 Role of calcitriol and cortisol on human adipocyte proliferation and oxidative and inflammatory stress: a microarray study. J Nutrigenet Nutrigenomics. 2008;1(1-2):30-48. doi: 10.1159/000109873. Epub 2007 Oct 16.
47 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
48 Stem cell transcriptome responses and corresponding biomarkers that indicate the transition from adaptive responses to cytotoxicity. Chem Res Toxicol. 2017 Apr 17;30(4):905-922.
49 Regulation of ERRalpha gene expression by estrogen receptor agonists and antagonists in SKBR3 breast cancer cells: differential molecular mechanisms mediated by g protein-coupled receptor GPR30/GPER-1. Mol Endocrinol. 2010 May;24(5):969-80. doi: 10.1210/me.2009-0148. Epub 2010 Mar 8.
50 The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
51 Troglitazone induces cytotoxicity in part by promoting the degradation of peroxisome proliferator-activated receptor co-activator-1 protein. Br J Pharmacol. 2010 Oct;161(4):771-81. doi: 10.1111/j.1476-5381.2010.00900.x.
52 Plasmatic concentration of organochlorine lindane acts as metabolic disruptors in HepG2 liver cell line by inducing mitochondrial disorder. Toxicol Appl Pharmacol. 2013 Oct 15;272(2):325-34.
53 Antiepileptic drugs are endocrine disruptors for the human fetal testis ex vivo. Toxicol Sci. 2023 Sep 28;195(2):169-183. doi: 10.1093/toxsci/kfad076.
54 The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide. Exp Hematol. 2011 Jan;39(1):55-65.
55 [Regulation of orphan receptor ERR alpha by estrogen and progesterone in endometrial carcinoma cell line]. Beijing Da Xue Xue Bao Yi Xue Ban. 2005 Jun 18;37(3):281-3.
56 Gene expression profile induced by BCNU in human glioma cell lines with differential MGMT expression. J Neurooncol. 2005 Jul;73(3):189-98.
57 Inhibiting Heat Shock Proteins Can Potentiate the Cytotoxic Effect of Cannabidiol in Human Glioma Cells. Anticancer Res. 2015 Nov;35(11):5827-37.
58 Gene expression after treatment with hydrogen peroxide, menadione, or t-butyl hydroperoxide in breast cancer cells. Cancer Res. 2002 Nov 1;62(21):6246-54.
59 Expression profile analysis of colon cancer cells in response to sulindac or aspirin. Biochem Biophys Res Commun. 2002 Mar 29;292(2):498-512.
60 Development and validation of the TGx-HDACi transcriptomic biomarker to detect histone deacetylase inhibitors in human TK6 cells. Arch Toxicol. 2021 May;95(5):1631-1645. doi: 10.1007/s00204-021-03014-2. Epub 2021 Mar 26.
61 Simvastatin inactivates beta1-integrin and extracellular signal-related kinase signaling and inhibits cell proliferation in head and neck squamous cell carcinoma cells. Cancer Sci. 2007 Jun;98(6):890-9.
62 Identification of novel activators of the metal responsive transcription factor (MTF-1) using a gene expression biomarker in a microarray compendium. Metallomics. 2020 Sep 23;12(9):1400-1415. doi: 10.1039/d0mt00071j.
63 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
64 Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
65 Motexafin gadolinium and zinc induce oxidative stress responses and apoptosis in B-cell lymphoma lines. Cancer Res. 2005 Dec 15;65(24):11676-88.
66 SIRT3 Mediates the Antioxidant Effect of Hydrogen Sulfide in Endothelial Cells. Antioxid Redox Signal. 2016 Feb 20;24(6):329-43. doi: 10.1089/ars.2015.6331. Epub 2015 Nov 10.
67 Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
68 The p53/miR-34a/SIRT1 Positive Feedback Loop in Quercetin-Induced Apoptosis. Cell Physiol Biochem. 2015;35(6):2192-202. doi: 10.1159/000374024. Epub 2015 Apr 7.
69 AMPK activator acadesine fails to alleviate isoniazid-caused mitochondrial instability in HepG2 cells. J Appl Toxicol. 2017 Oct;37(10):1219-1224. doi: 10.1002/jat.3483. Epub 2017 May 29.
70 Arsenic trioxide induces apoptosis in NB-4, an acute promyelocytic leukemia cell line, through up-regulation of p73 via suppression of nuclear factor kappa B-mediated inhibition of p73 transcription and prevention of NF-kappaB-mediated induction of XIAP, cIAP2, BCL-XL and survivin. Med Oncol. 2010 Sep;27(3):833-42. doi: 10.1007/s12032-009-9294-9. Epub 2009 Sep 10.
71 Dual targeting of the antagonistic pathways mediated by Sirt1 and TXNIP as a putative approach to enhance the efficacy of anti-aging interventions. Aging (Albany NY). 2009 Mar 31;1(4):412-24. doi: 10.18632/aging.100035.
72 Hydroquinone-induced malignant transformation of TK6 cells by facilitating SIRT1-mediated p53 degradation and up-regulating KRAS. Toxicol Lett. 2016 Sep 30;259:133-142. doi: 10.1016/j.toxlet.2016.08.006. Epub 2016 Aug 8.
73 The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384. doi: 10.1016/j.taap.2020.115384. Epub 2020 Dec 25.
74 Iron overload inhibits cell proliferation and promotes autophagy via PARP1/SIRT1 signaling in endometriosis and adenomyosis. Toxicology. 2022 Jan 15;465:153050. doi: 10.1016/j.tox.2021.153050. Epub 2021 Nov 23.
75 Pleiotropic beta-agonist-promoted receptor conformations and signals independent of intrinsic activity. Am J Respir Cell Mol Biol. 2007 Feb;36(2):236-43. doi: 10.1165/rcmb.2006-0257OC. Epub 2006 Sep 15.
76 Development of 3D-QSAR models for predicting the activities of chemicals to stimulate muscle growth via (2)-adrenoceptor. Toxicol In Vitro. 2021 Dec;77:105251. doi: 10.1016/j.tiv.2021.105251. Epub 2021 Sep 30.
77 Beta2-adrenergic receptor polymorphisms in African American children with status asthmaticus. Pediatr Crit Care Med. 2006 Jan;7(1):15-8. doi: 10.1097/01.pcc.0000194010.63115.a2.
78 beta2-adrenergic receptor polymorphisms and salbutamol-stimulated energy expenditure. J Clin Endocrinol Metab. 2005 Apr;90(4):2301-7. doi: 10.1210/jc.2004-1356. Epub 2005 Feb 1.
79 Neutrophil beta(2)-adrenoceptor function in major depression: G(s) coupling, effects of imipramine and relationship to treatment outcome. Eur J Pharmacol. 1999 Dec 15;386(2-3):135-44. doi: 10.1016/s0014-2999(99)00749-9.
80 Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
81 Myocardial ischaemia and ventricular arrhthymias precipitated by physiological concentrations of adrenaline in patients with coronary artery disease. Br Heart J. 1992 May;67(5):419-20. doi: 10.1136/hrt.67.5.419-b.
82 Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
83 Hormonal regulation of beta2-adrenergic receptor level in prostate cancer. Prostate. 2008 Jul 1;68(10):1133-42. doi: 10.1002/pros.20778.
84 Histamine augments beta2-adrenoceptor-induced cyclic AMP accumulation in human prostate cancer cells DU-145 independently of known histamine receptors. Biochem Pharmacol. 2007 Mar 15;73(6):814-23. doi: 10.1016/j.bcp.2006.11.022. Epub 2006 Dec 1.
85 Simvastatin inhibits IL-17 secretion by targeting multiple IL-17-regulatory cytokines and by inhibiting the expression of IL-17 transcription factor RORC in CD4+ lymphocytes. J Immunol. 2008 May 15;180(10):6988-96. doi: 10.4049/jimmunol.180.10.6988.
86 Induction of heme oxygenase-1 by cobalt protoporphyrin enhances the antitumour effect of bortezomib in adult T-cell leukaemia cells. Br J Cancer. 2007 Oct 22;97(8):1099-105. doi: 10.1038/sj.bjc.6604003. Epub 2007 Sep 25.
87 Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.